Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
65.14
+0.42 (0.65%)
Aug 13, 2025, 4:00 PM - Market closed
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $127.79M in the quarter ending June 30, 2025, with 64.09% growth. This brings the company's revenue in the last twelve months to $429.16M, up 62.33% year-over-year. In the year 2024, Mirum Pharmaceuticals had annual revenue of $336.89M with 80.76% growth.
Revenue (ttm)
$429.16M
Revenue Growth
+62.33%
P/S Ratio
7.38
Revenue / Employee
$1,332,798
Employees
322
Market Cap
3.27B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MIRM News
- 2 days ago - Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum - Seeking Alpha
- 7 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 14 days ago - Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - Business Wire
- 3 months ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL - Business Wire